menu
    • menu
    [{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BA1202","moa":"CEA","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY06006","moa":"Denosumab receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LY06006","moa":"Denosumab receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY06006","moa":"Denosumab receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY01008","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LY-CovMab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LY01011","moa":"TNFSF11","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Boan Biotech"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY01015","moa":"Trastuzumab receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BA1105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BA1106","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BA1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BA1302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Luye Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"LY09004","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boan Biotech \/ Boan Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Boan Biotech \/ Boan Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Boan Biotech

    Menu

    Boan Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA1301

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Soli...

                            Details : BA1301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : BA1301

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA1302

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

                            Details : BA1302 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : BA1302

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY01015

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy i...

                            Details : LY01015 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophageal Squamous Cell Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 05, 2023

                            Lead Product(s) : LY01015

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA1202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of BA1202 in Patients With Advanced Solid Tumors

                            Details : BA1202 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 18, 2023

                            Lead Product(s) : BA1202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA1106

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Soli...

                            Details : BA1106 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 14, 2022

                            Lead Product(s) : BA1106

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY01008

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chi...

                            Details : LY01008 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 05, 2021

                            Lead Product(s) : LY01008

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA1105

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Boan Biotech’s New ADCC-Enhanced Anti-Claudin 18.2 Antibody Drug BA1105 Approved for Clinical Trials in Chin...

                            Details : BA1105 is a recombinant anti-Claudin18.2 human IgG1 monoclonal antibody for treating Claudin18.2-positive advanced solid tumors. BA1105 alone or in combination with chemotherapeutic agents demonstrated a strong anticancer activity in tumor models.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 05, 2021

                            Lead Product(s) : BA1105

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY06006

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Recipient : Luye Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk ...

                            Details : LY06006 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : LY06006

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Recipient : Luye Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY06006

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Luye Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate LY06006 and Prolia in Healthy Adults

                            Details : LY06006 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : LY06006

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Luye Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed

                            Boan Biotech

                            China arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY-CovMab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Luye Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects

                            Details : LY-CovMab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : LY-CovMab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Luye Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth